Q3 EPS Estimates for Krystal Biotech Cut by William Blair

Key Points

• William Blair has revised down its Q3 2025 EPS forecast for Krystal Biotech from $1.38 to $1.14, while the full-year earnings consensus stands at $6.14 per share.
• Despite the EPS revision, Krystal Biotech reported a Q2 2025 EPS of $1.29, surpassing analyst expectations of $1.08 and achieving $96.04 million in revenue.
• Institutional interest in Krystal Biotech is strong, with 86.29% of the stock owned by institutional investors, and notable increases in holdings from firms like Mitsubishi UFJ Asset Management and Aviva PLC.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at William Blair reduced their Q3 2025 EPS estimates for shares of Krystal Biotech in a research report issued to clients and investors on Monday, August 4th. William Blair analyst S. Corwin now forecasts that the company will post earnings of $1.14 per share for the quarter, down from their previous forecast of $1.38. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's Q1 2026 earnings at $1.40 EPS, Q2 2026 earnings at $1.88 EPS, Q3 2026 earnings at $2.16 EPS, Q4 2026 earnings at $2.93 EPS and FY2026 earnings at $8.37 EPS.

Several other brokerages have also weighed in on KRYS. Bank of America dropped their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research report on Tuesday, July 22nd. Citigroup reiterated a "neutral" rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Guggenheim decreased their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Chardan Capital reissued a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $210.22.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $0.16 on Thursday, reaching $138.50. The company had a trading volume of 110,964 shares, compared to its average volume of 333,589. The firm has a market capitalization of $4.01 billion, a PE ratio of 28.15 and a beta of 0.70. The firm has a 50-day moving average of $141.94 and a 200-day moving average of $155.38. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%.

Institutional Investors Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of KRYS. Brooklyn Investment Group boosted its holdings in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Krystal Biotech by 8,950.0% during the 2nd quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock valued at $25,000 after acquiring an additional 179 shares in the last quarter. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech during the 1st quarter valued at $29,000. Fifth Third Bancorp boosted its holdings in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after acquiring an additional 105 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares in the company, valued at $216,924,382.80. This trade represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 in the last 90 days. 13.70% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).